NeuBase Therapeutics, Inc. stock is up 4.76% since 30 days ago. The next earnings date is Dec 20, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.63% of the previous 19 November’s closed higher than October.
NeuBase Therapeutics, Inc. focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.